target in glioma immunotherapy, especially in formulations of customized vaccines. The lack of humoral and cellular reactions in the blood and tumors of patients with lower-grade gliomas (LGGs) suggested that IDH1 R132H is not immunogenic enough and discourages its potential for future therapeutic use, at least in most LGG patients. Here, IDH1 is linked to central nervous system cancer.